Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 3/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19478707 | 0.98 | ALOX5 (0.36) | ALOX5FAAHMGLLGAACCR2 | |
| SCHEMBL19478690 | 0.95 | ALOX5 (0.35) | ALOX5FAAHMGLLGAACCR2 | |
| SCHEMBL26946645 | 0.95 | ALOX5 (0.40) | ALOX5FAAHMGLLGAACCR2 | |
| SCHEMBL26946782 | 0.95 | ALOX5 (0.40) | ALOX5FAAHMGLLGAACCR2 | |
| SCHEMBL19918770 | 0.94 | MITF (0.33) | ALOX5GAAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL21922559 | 0.94 | ALOX5 (0.41) | ALOX5FAAHMGLLGAACCR2 | |
| SCHEMBL18799294 | 0.94 | ALOX5 (0.41) | ALOX5FAAHMGLLGAACCR2 | |
| SCHEMBL23346883 | 0.87 | FAAH (0.38) | ALOX5FAAHMGLLCCR2CCR1 | |
| SCHEMBL29300320 | 0.87 | FAAH (0.38) | ALOX5FAAHMGLLCCR2CCR1 | |
| SCHEMBL19453101 | 0.86 | ALOX5 (0.36) | ALOX5FAAHMGLLGAACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ALOX5 235/4885FAAH 282/4885MGLL 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.